Redx Confirms Proposed Business Combination with Jounce has Formally Lapsed
April 3, 2023Business Services
Alderley Park, UK, 3 April 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
March 31, 2023Business Services Almirall, Dermatology, dermatology, lebrikizumab
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 31, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that …
Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease
March 31, 2023Medical Communications
Abbott has announced that the FDA has approved its Epic Max stented tissue valve to treat patients with aortic regurgitation …
First over-the-counter opioid overdose treatment approved by FDA
March 31, 2023Medical Communications
The FDA has announced that it has approve Narcan, 4mg naloxone hydrochloride nasal spray for over-the-counter (OTC), non-prescription use. This …
NEC streamlines AI drug development with subsidiary reshuffle
March 31, 2023Medical Communications
Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. …
Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa
March 31, 2023Medical Communications
US-based Nanoscope Therapeutics has announced topline results from its phase 2b RESTORE clinical trial. Currently, patients with vision loss due …
Expansion of Scientific Affairs Group
March 30, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Roz Bekker appointed Managing Director of Janssen UK & Ireland
March 30, 2023Business Services
High Wycombe, UK, 30 March 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to introduce Roz …
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
March 30, 2023Business Services
London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating …
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
March 30, 2023Business Services
Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced …
PHARMANOVIA EXPANDS EXCLUSIVE LICENSING COLLABORATION WITH AQUESTIVE THERAPEUTICS FOR DIAZEPAM BUCCAL FILM
March 30, 2023Business Services
Basildon, UK – For immediate release, 27 March 2023 Pharmanovia, a global pharmaceutical company that revitalises, extends and expands …
Unite Health: Thousands Honor Pandemic ‘Influencers’ Through COVID-19 Social Media Awards
March 30, 2023Business Services
London, UK | In a global display of appreciation, thousands of people are recognizing social media influencers who used …
UK and Polish regulatory authorities approve Akari Therapeutics’ higher-yielding manufacturing process
March 30, 2023Manufacturing and Production
Akari Therapeutics has announced that the UK’s MHRA and the Polish Office for Registration of Medicinal Products, Medical Devices and …
Hovione and Laxxon Medical sign partnership over 3D printed pharmaceutical applications
March 30, 2023Medical Communications
Hovione, a CDMO, and Laxxon Medical, a pharma-technology company, have signed a strategic partnership deal to bring 3D printing technologies …
Janssen reports new Rybrevant data for patients with advanced non-small cell lung cancer
March 30, 2023Research and Development
Janssen, part of Johnson & Johnson, has announce new long-term data from its CHRYSALIS study, which assessed Rybrevant (amivantamab) in …
Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028
March 30, 2023Sales and Marketing
After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a …
Netris Pharma doses first patient in pancreatic cancer study
March 29, 2023Research and Development
Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy …
AbbVie’s upadacitinib meets primary endpoint in trial for systemic lupus erythematosus
March 29, 2023Research and Development
AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus …
Genialis raises $13m in Series A funding for the development of AI/ML patient classifiers
March 29, 2023Medical Communications
Genialis, a computational precision medicine company, has announced that it’s raised more than $13m in Series A funding, co-led by …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
